MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells

Das, A. ; Henderson, F. C. ; Alshareef, M. ; Porto, G. B. F. ; Kanginakudru, I. ; Infinger, L. K. ; Vandergrift, W. A. ; Lindhorst, S. M. ; Varma, A. K. ; Patel, S. J. ; Cachia, D.

Clinical & translational oncology, 2021-03, Vol.23 (3), p.612-619 [Periódico revisado por pares]

Cham: Springer International Publishing

Texto completo disponível